Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Lifson JD, Haigwood NL.

Cold Spring Harb Perspect Med. 2012 Jun;2(6):a007310. doi: 10.1101/cshperspect.a007310.

2.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH.

N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.

3.

Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.

Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR.

J Virol. 2012 May;86(10):5844-56. doi: 10.1128/JVI.07139-11. Epub 2012 Mar 14.

4.

The Antibody Response against HIV-1.

Overbaugh J, Morris L.

Cold Spring Harb Perspect Med. 2012 Jan;2(1):a007039. doi: 10.1101/cshperspect.a007039. Review.

5.

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.

Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL.

Nature. 2012 Jan 4;482(7383):89-93. doi: 10.1038/nature10766.

6.

Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

de Silva TI, Aasa-Chapman M, Cotten M, Hué S, Robinson J, Bibollet-Ruche F, Sarge-Njie R, Berry N, Jaye A, Aaby P, Whittle H, Rowland-Jones S, Weiss R.

J Virol. 2012 Jan;86(2):930-46. doi: 10.1128/JVI.06126-11. Epub 2011 Nov 9.

7.

Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.

Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, Kiviat NB, Sow PS, Georgiev I, Hahn BH, Kwong PD, Robinson JE, Shaw GM.

J Virol. 2012 Jan;86(2):947-60. doi: 10.1128/JVI.06155-11. Epub 2011 Oct 26.

8.

The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys.

Yeh WW, Rao SS, Lim SY, Zhang J, Hraber PT, Brassard LM, Luedemann C, Todd JP, Dodson A, Shen L, Buzby AP, Whitney JB, Korber BT, Nabel GJ, Mascola JR, Letvin NL.

J Virol. 2011 Oct;85(19):10389-98. doi: 10.1128/JVI.00854-11. Epub 2011 Jul 20.

9.

The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge.

Reynolds MR, Sacha JB, Weiler AM, Borchardt GJ, Glidden CE, Sheppard NC, Norante FA, Castrovinci PA, Harris JJ, Robertson HT, Friedrich TC, McDermott AB, Wilson NA, Allison DB, Koff WC, Johnson WE, Watkins DI.

J Virol. 2011 Sep;85(18):9637-40. doi: 10.1128/JVI.05074-11. Epub 2011 Jul 6.

10.

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.

Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, Johnson WE, Hirsch V, Villinger F, Chennareddi L, Earl PL, Moss B, Amara RR, Robinson HL.

J Infect Dis. 2011 Jul 1;204(1):164-73. doi: 10.1093/infdis/jir199.

11.

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L; CAPRISA 002 Study.

J Virol. 2011 Apr;85(7):3128-41. doi: 10.1128/JVI.02658-10. Epub 2011 Jan 26.

12.

B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection.

Huang KH, Bonsall D, Katzourakis A, Thomson EC, Fidler SJ, Main J, Muir D, Weber JN, Frater AJ, Phillips RE, Pybus OG, Goulder PJ, McClure MO, Cooke GS, Klenerman P.

Nat Commun. 2010 Oct 19;1:102. doi: 10.1038/ncomms1100.

13.

TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species.

Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, O'Connor S, Marx PA, Meythaler M, Goldstein S, Buckler-White A, Kaur A, Hirsch VM, Johnson WE.

PLoS Biol. 2010 Aug 24;8(8). pii: e1000462. doi: 10.1371/journal.pbio.1000462.

14.

Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level.

Bunnik EM, Euler Z, Welkers MR, Boeser-Nunnink BD, Grijsen ML, Prins JM, Schuitemaker H.

Nat Med. 2010 Sep;16(9):995-7. doi: 10.1038/nm.2203. Epub 2010 Aug 29.

PMID:
20802498
15.

Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Yeh WW, Rahman I, Hraber P, Coffey RT, Nevidomskyte D, Giri A, Asmal M, Miljkovic S, Daniels M, Whitney JB, Keele BF, Hahn BH, Korber BT, Shaw GM, Seaman MS, Letvin NL.

J Virol. 2010 Jun;84(12):6018-32. doi: 10.1128/JVI.02741-09. Epub 2010 Mar 31.

16.

Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H.

J Infect Dis. 2010 Apr 1;201(7):1045-53. doi: 10.1086/651144.

17.

Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.

van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, Schuitemaker H.

J Virol. 2010 Apr;84(7):3576-85. doi: 10.1128/JVI.02622-09. Epub 2010 Jan 13.

18.

Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H.

J Gen Virol. 2010 May;91(Pt 5):1354-64. doi: 10.1099/vir.0.017319-0. Epub 2010 Jan 6.

PMID:
20053822
19.

Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.

Bunnik EM, Lobbrecht MS, van Nuenen AC, Schuitemaker H.

Virology. 2010 Feb 5;397(1):224-30. doi: 10.1016/j.virol.2009.11.009. Epub 2009 Nov 27.

20.

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L; CAPRISA 002 Study; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

PLoS Pathog. 2009 Sep;5(9):e1000598. doi: 10.1371/journal.ppat.1000598. Epub 2009 Sep 18.

Items per page

Supplemental Content

Write to the Help Desk